- Home
- WSC vs LEGN Comparison
WSC vs LEGN Comparison
Compare WSC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | LEGN |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WSC | LEGN |
|---|---|---|
| Price | $16.49 | $18.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $26.20 | ★ $45.62 |
| AVG Volume (30 Days) | ★ 2.6M | 1.9M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $2,281,446,000.00 | N/A |
| Revenue This Year | $1.31 | $39.73 |
| Revenue Next Year | $2.24 | $23.42 |
| P/E Ratio | $40.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.91 | $16.24 |
| 52 Week High | $29.77 | $37.50 |
Technical Indicators
Market Signals| Indicator | WSC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 49.54 |
| Support Level | N/A | $17.08 |
| Resistance Level | $18.76 | $19.92 |
| Average True Range (ATR) | 0.72 | 0.87 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 38.51 | 57.63 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.